Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Xena - You're the best. My best to you. God bless.
We can be Heroes. Forever and ever. What's you say?
Nice Jimmy! Get ready for the Superbowl of CNS drug-disease winners. Who can beat A2-73? Let's hear it. Let's see it.
Fantastic George. Thanks.
Video documentation of people taking A2-73 is feeling better is proof that the drug works. IMO. Let it be so.
Right. Maybe helped to stael our mony from $14.00 share? Imo. GL.
Remove the corruption. IMO
Remove the corruption.
Nidan. Great assessment. Thank you.
Something is coming tomorrow. More corruption.
Remove the corruption.
The real question is has this country gotten so corrupt that even something good will not be accepted. That's the real question.
Nice George. Didn't know that as coming up. Thanks for sharing. GL
A2-73 has five years of positive data in the CNS space. What other drug matches that?
Thumbs Up! Nice.
All IMO opinion.
Guess what. We accidentally found a cure for cancer. Wow. Guess what. We accidental found a cure for Alzheimer. Wow.
Right. Good one Wolf.
A2-73 speaks for its self with 5 years of positive test results in the CNS space. What other medication beats 2-73?
Anders - I'm very sorry about your son's condition. I am not the person to comment on your question. Several on this board are. Good luck to you. Best.
5 years' worth of positive A2-73 data in Alzheimer's dementia space. That is getting something done. Who else is done that?
Reyton - This is huge. This patent was for 5 neurodevelopment disorders. Worth a lot of money.
The United States Patent and Trademark Office (USPTO) granted a patent to Anavex Life Sciences covering Anavex 2-73 (blarcamesine) as a potential therapy for neurodevelopmental disorders, including Rett syndrome.
The patent (No. 10,507,196) is valid until at least 2037 and also covers methods of treatment based on Anavex 2-73 for other disorders including multiple sclerosis, Angleman Syndrom, Cerebral Palsy and Autism spectrum disorders.
Right. People that are taking A2-73 are feeling better and its documented publicly. Look at CTAD results. The drug works.
Nice post Aero. Very accurate in detail. IMO. Hopefully, we get this turned around. GL.
Squid - Not so sure about that. Could see a flight to quality in A2-73.
Getting ready to send some precision medicine to Iran.
166 million MC. What a joke. We should be at a 2 to 2.5 billion market cap
with current reported CTAD results.IMO
People who are looking for news. You have it right here.
https://finance.yahoo.com/news/anavex-life-sciences-presents-anavex-120010950.html
Right. I worked shift work for 18 years and now I have sleep issues as well. Back in those days it was not well understood how bad it was for your body. As I learn more about CNS disease I can see how sleep issues seem to be a precursor. I use liquid melatonin as someone shared on this board and its a big help. As you said chicken and egg thing. Thank you.
Sleep disorders- I am surprised that AVXL did not push A2-73 approval with sleep disorder issues. Everything I have read about 2-73 and sleep results are outstanding. The sleep disorder market is huge in and of its self. Thoughts?
You are sounding pretty accurate to me. AVXL should have a 3 to 5 billion market cap. $60.00 per share.
Right! AVXL CTAD 2-73 information showed blockbuster results. There is no other drug that comes close to these positive results. Should be the new SOC with these results and proven safety. The market was silent with it as daily volumes increased since then. GL
Propensity score matching (PSM) was applied using Linear Mixed Effects (LME) models including descriptors of age, sex, SIGMAR1 p.Q2P carrier status, APOE4 allele and MMSE at baseline to select patients with similar baseline characteristics and any confounding factors between AD patients in the Phase 2a ANAVEX®2-73 (blarcamesine) cohort and AD patients from the ADNI control cohort.
Change in MMSE score from baseline at week 104 of matched cohorts was assessed. It showed that ANAVEX®2-73 (blarcamesine) high dose cohort had a significantly lower MMSE decline (-1.1) compared to the ADNI control cohort (-4.4) at week 104 (p < 0.01).
https://finance.yahoo.com/news/anavex-life-sciences-presents-anavex-120010950.html
Right. We should have BIIB give the same results and have a 20 billion mc added in one day.
Right. Is the market crooked? Should be the new standard of care.
A2-73 A gift from God. Happy New Year folks.
Xena. Thanks for all you do for this board. Like you, I cant wait to try 2-73. I have four different areas that this drug is proving to have positive results with. At 58 I believe it can help extend my life for another 10 years or so. Merry Christmas and Happy New Year to you. Best
Bravo, Falconer66a. That was an awesome explanation. Merry Christmas and New Year to you. Best
People on the river are happy to give. Big wheels keep on turning with 2-73.
We can be heroes for ever and ever!.
Right. This is a blockbuster drug with great results. Data shows that it works.